SANOFI PASTEUR

🇫🇷France

Country: 🇫🇷France

Ownership: Subsidiary

Established: 1990-01-01

Employees: 10K

Market Cap: -

Website: http://www.sanofipasteur.com

Clinical Trials

Prospective Surveillance of Respiratory Syncytial Virus Disease in Infants and Toddlers

Active, not recruiting

Conditions: Respiratory Syncytial Virus Infections

First Posted Date: 2023-07-28

Last Posted Date: 2024-02-29

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 1000

Registration Number: NCT05964582

Locations: 🇭🇳
Investigational Site Number : 3400001, Tegucigalpa, Honduras
🇫🇮
Investigational Site Number : 2460001, Järvenpää, Finland
🇫🇮
Investigational Site Number : 2460003, Tampere, Finland

and more 12 locations

Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy

Phase 4

Recruiting

Conditions: Meningococcal Immunisation
Healthy Volunteers

Interventions: Biological: MenACYW conjugate vaccine

First Posted Date: 2023-07-03

Last Posted Date: 2024-05-30

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 180

Registration Number: NCT05929651

Locations: 🇦🇷
Investigational Site Number : 0320002, Buenos Aires, Ciudad De Buenos Aires, Argentina
🇦🇷
Investigational Site Number : 0320001, Ciudad Autonoma Buenos Aires, Argentina

Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above

Phase 1

Completed

Conditions: Influenza Immunization

Interventions: Biological: H3 mRNA / LNP Vaccine
Biological: Quadrivalent recombinant influenza Vaccine (RIV4)

First Posted Date: 2023-04-25

Last Posted Date: 2024-05-09

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 159

Registration Number: NCT05829356

Locations: 🇬🇧
Investigational Site Number : 8260001, London, London, City Of, United Kingdom
🇬🇧
Investigational Site Number : 8260003, Sheffield, United Kingdom
🇦🇺
Investigational Site Number : 0360004, Herston, Queensland, Australia

and more 5 locations

Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa

Phase 3

Active, not recruiting

Conditions: Meningococcal Immunisation
Healthy Volunteers

Interventions: Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Biological: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Biological: Pneumoccocal Vaccine
Biological: Oral bivalent types 1 and 3; Poliomyelitis Vaccine (OPV)
Biological: Measles, Mumps, and Rubella Vaccine live (MMR)
Biological: DTwP-HepB-Hib-IPV vaccine
Biological: DTaP-IPV-Hib-HepB vaccine
Biological: Rotavirus vaccine
Biological: Hepatitis A vaccine
Biological: Measles vaccine
Biological: Varicella vaccine live
Biological: Typhoid conjugate vaccine (TCV)

First Posted Date: 2023-04-03

Last Posted Date: 2024-11-27

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 1528

Registration Number: NCT05794230

Locations: 🇮🇳
Investigational Site Number : 3560006, Chennai, India
🇮🇳
Investigational Site Number : 3560007, Hyderabad, India
🇮🇳
Investigational Site Number : 3560016, Kanpur, India

and more 12 locations

Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA)

Phase 1

Completed

Conditions: Respiratory Syncytial Virus Infection

Interventions: Other: Control Group
Biological: RSVt Vaccine

First Posted Date: 2023-01-18

Last Posted Date: 2025-02-06

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 80

Registration Number: NCT05687279

Locations: 🇺🇸
Meridian Clinical Research Norfolk Site Number : 8400003, Norfolk, Nebraska, United States
🇵🇷
Investigational Site Number : 6300004, Bayamón, Puerto Rico
🇺🇸
Velocity Clinical Research, Omaha Site Number : 8400001, Omaha, Nebraska, United States

and more 3 locations

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older

Phase 1

Completed

Conditions: Influenza Immunization

Interventions: Biological: Quadrivalent Influenza mRNA Vaccine MRT5413
Biological: Quadrivalent Influenza Standard Dose Vaccine
Biological: Quadrivalent Influenza High-Dose Vaccine
Biological: Quadrivalent Recombinant Influenza Vaccine

First Posted Date: 2022-12-14

Last Posted Date: 2025-03-19

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 682

Registration Number: NCT05650554

Locations: 🇺🇸
Velocity Clinical Research-Chula Vista Site Number : 8400061, Chula Vista, California, United States
🇺🇸
Velocity Gardena Site Number : 8400062, Gardena, California, United States
🇺🇸
Long Beach Clinical Trials Site Number : 8400052, Long Beach, California, United States

and more 32 locations

Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older

Phase 1

Active, not recruiting

Conditions: Respiratory Syncytial Virus Immunization

Interventions: Biological: RSV vaccine candiate formulation 1
Other: Placebo
Biological: RSV vaccine candidate formulation 2

First Posted Date: 2022-12-07

Last Posted Date: 2024-05-03

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 865

Registration Number: NCT05639894

Locations: 🇺🇸
Velocity Clinical Research Site Number : 8400018, West Jordan, Utah, United States
🇺🇸
Velocity Clinical Research, Medford Site Number : 8400014, Medford, Oregon, United States
🇺🇸
Optimal Research Alabama Site Number : 8400032, Huntsville, Alabama, United States

and more 34 locations

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older

Phase 1

Completed

Conditions: Influenza Immunization

Interventions: Biological: Quadrivalent Inactivated Influenza High Dose QIV-HD
Biological: Quadrivalent Inactivated Influenza Standard Dose QIV-SD
Biological: Quadrivalent Influenza mRNA Vaccine MRT5410
Biological: Quadrivalent Recombinant Influenza vaccine RIV4

First Posted Date: 2022-11-22

Last Posted Date: 2025-03-18

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 682

Registration Number: NCT05624606

Locations: 🇺🇸
Indago Research and Health Center Site Number : 8400002, Hialeah, Florida, United States
🇺🇸
Joint Clinical Trials Huntington Park Site Number : 8400032, Huntington Park, California, United States
🇺🇸
Velocity Clinical Research, North Hollywood Site Number : 8400063, North Hollywood, California, United States

and more 22 locations

Burden of Respiratory Syncytial Virus (RSV) in Children in Sweden (BRICS): A Retrospective Study in Sweden

Completed

Conditions: Respiratory Syncytial Virus (RSV)

First Posted Date: 2022-11-18

Last Posted Date: 2024-05-14

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 1100000

Registration Number: NCT05622331

Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older

Phase 1

Completed

Conditions: Influenza
Healthy Volunteers

Interventions: Biological: Panblok + MF59 Dose 1
Biological: Unadjuvanted Panblok Dose 3
Biological: Panblok + MF59 Dose 2

First Posted Date: 2022-11-07

Last Posted Date: 2025-02-20

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 581

Registration Number: NCT05608005

Locations: 🇺🇸
Velocity Clinical Research Anderson Site Number : 8400016, Anderson, South Carolina, United States
🇺🇸
Suncoast Research Associates, LLC Site Number : 8400008, Miami, Florida, United States
🇺🇸
Preferred Primary Care Physicians, Inc. Site Number : 8400002, Pittsburgh, Pennsylvania, United States

and more 13 locations

Home Terms & Conditions Privacy Policy